Log In
Print
BCIQ
Print
Print this Print this
 

Pinatuzumab vedotin (DCDT2980S, RG7593)

Also known as: anti-CD22 ADC

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-CD22 mAb and monomethyl auristatin E (MMAE)
Molecular Target CD22
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today